Vertex posts Phase 4 results for suzetrigine in post-surgical acute pain
Vertex Pharmaceuticals reported results from a completed Phase 4 study of suzetrigine (Journavx) for acute pain after aesthetic or reconstructive surgery.
Vertex had one item posted for the week of November 16, 2026.
- Suzetrigine (SUZ, VX-548, Journavx), a Phase 4 single-arm study in acute pain following aesthetic or reconstructive surgery, is listed as completed with primary completion on 2025-10-24 and results posted on 2026-11-16. Across 99 evaluable participants, 90.7% reported good, very good, or excellent pain control on the Patient Global Assessment at the end of treatment, with 3 of 99 participants experiencing serious adverse events.1 The study enrolled 100 participants and used an enrollment of 100 participants (actual) under a single-group, open-label design.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.